| REVIEW ARTICLE |
|
| Year : 2019 | Volume
: 7
| Issue : 1 | Page : 3-7 |
|
|
Aspirin for primary prevention: The changing paradigms!
Akshyaya Kumar Pradhan, Vikas Gupta, Pravesh Vishwakarma
Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
Correspondence Address:
Dr. Akshyaya Kumar Pradhan
Department of Cardiology, King George's Medical University, Lucknow - 226 007, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/heartindia.heartindia_5_19
|
|
|
Aspirin has been a widely used antiplatelet drug for management of cardiovascular disease for last five decades. Multiple studies have established its role in secondary prevention of cardiovascular diseases. For primary prevention, the situation is not so simple. Initial studies (though large and with long follow up) performed two decades ago suggested an impressive positive risk -benefit profile. But such benefits could not be replicated in subsequent studies performed in the new millennium. Recently, three back to back studies of aspirin in primary prevention in contemporary era failed to demonstrate any benefits or the benefits were counterbalanced by bleeding events. Hence, the role of aspirin for primary prevention of cardiovascular disease is under intense scrutiny.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
